Meet the new ZNZ group leaders
New ZNZ research group leaders:
Shiva Tyagarajan, PhD
Institute of Pharmacology and Toxicology, University of Zurich
The focus of Dr. Tyagarajan’s group is on the identification of molecular mechanisms that regulate the postsynaptic apparatus at inhibitory synapses to uncover novel regulatory switches that facilitate rapid adaptations in GABAergic transmissions. Shiva Tyagarajan has been a ZNZ junior research group leader since May 2014.
PD Dr. Simone Hornemann
Institute of Neuropathology, University Hospital Zurich
The primary research interest of Simone Hornemann lies in the understanding of the molecular mechanisms of protein misfolding and aggregation diseases, such as e.g. prion, Parkinson’s and Alzheimer disease. One goal is to clarify whether common mechanisms underlie all those diseases and ultimately to develop new small-molecule diagnostic and therapeutic strategies.
PD Dr. Giovanni G. Camici
Center for Molecular Cardiology, University of Zurich, Schlieren
Giovanni Camici’s current and future research concentrates on vascular aspects (i.e. blood brain barrier) and neuromotor deficits resulting from stroke. In addition, he is interested in the molecular mechanisms of age-induced cerebrovascular dysfunction and disease.
New ZNZ junior research group leader
Luka Kulic, MD
Division of Psychiatry Research and Psychogeriatric Medicine, University of Zurich, Schlieren
Luka Kulic’s research areas of interest include: Neurovascular and brain-immune mechanisms in neurodegenerative brain disorders; mechanisms of brain ageing and neurodegeneration, transgenic models and biomarkers in neurodegenerative disorders.